Antagonist Agents in Opiate Addiction: Naltrexone
Keywords:
Opiate Addiction, Antagonist agent, Addiction treatmentAbstract
Naltrexone is a spesific opioid antagonist that has a relatively long duration of action such that it can be used in aiding in the prevention of relaps to opioid dependence. Naltrexone is safe and relatively non-toxic.The antagonist treatment option is important to make available to well-motivated addicted individuals who desire to become drug free.As with all medication in the treatment of addiction, naltrexone must be used within a comprehensive treatment program, including individual or family psychotherapy and urine testing for illicit drugs.treatment should be continue for at least 3 months after detoxification and in many cases longer because there is a significant risk of relaps continuing for several years. There are many resarches in medications development.Several medications currently under study will add to the options for treatment in next several years.A depot form of naltexone that gives protection against relaps for 30-60 days is under study.Recent clinical trials in alcoho- lies suggest that naltexone may reduce the frequency of relapse in an outpatient rehabilitation program.
References
O’Brien, C.P.; Opioid addiction, in Handbook of Experimental Pharmacology. Edited by Herz Akil H, Simon HJ. Berlin, Springer-Verlag, 1992, 803-823-
Greenstein, R.A., Arndt, I.C., McLellan, A.T. et al; Naltrexone: a clinical perspective. J Clin Psychiatry 45:25-28, 1984.
Martin, W., Jasinski, D., Mansky, P. Naltrexone.; an antagonist for the treatment of heroin dependence. Arch Gen Psychiatry 28:784-791, 1973
O’Brien, C.P., Greenstein, R., Mintz, J. et al.; Clinical experience with naltrexone. Am J Drug Alcohol Abuse 2:365-377, 1975.
Ellingboe, J., Mendelson, J.H., Ku-ehnle, J.C.; Effects of heroin and naltrexone on plasma prolactin levels in man. Pharmacol Biochem Behav 12:163-165, 1980.
Mendelson, J.H., Ellingboe, J., Ku-ehnle, J.C. et al.; Heroin and naltrexone effects on pituitary-gonadal hormones in man: interaction of steroid feedback effects, tolerance and supersensitivity. J Pharmacol Exp Ther 214:503-506, 1980.
Spiegel, T., Stunkard, A.J., Shrager, E. et al.; Effect of naltrexone on food intake, hunger, and satiety in obese men. Psysiol Behav 40:135-141,1987.
Brahen, L.S., Henderson, R.K., Copone, T. et al.; Naltrexone treatment in a jail work-release program. J Clin Psychiatry 45:49-52, 1984.
Tennant, E, Rawson, R., Cohen. A. et al.; A clinical experience with naltrexone in suburban opioid addicts. J Clin Psychiatiy 45:42-45, 1984.
Washton, A.M., Pottash, A.C., Gold, M.S.; Naltrexone in addicted business executives and psysicians. J Clin Psychiatry 45:39-41, 1984.
Sideroff, S.I., Charuvastra, V.C., Jarvik, M.E.; Craving in heroin addicts maintained on the opiate antagonist naltrexone. Am J Dmg Alcohol Abuse 5:415-423, 1978.
Meyer, R.E., Mirin, S.M., Altman, J.L.; The clinical usefulness of narcotic antagonists: implications of behavioral research. Am J Drug and Alcohol Abuse. 2:417-432, 1975.
Cornish, J.W., Henson, D.,Levine, S. et al.; Naltrexone maintenance: effect on morphine sensitivity in normal volunteers. American Journal on Addictions 2:34-38, 1993.
Tilly, J., O’Brien, C.P., McLellan, A.T. et al.; Naltrexone in the treatment of federal probationers, in Problems of Drug Dependence 1991, Proceedings of the 53rd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, NIDA Res Monogr 119 (Publ No ADM-92-188). Edited Harris L, Washington, DC, U.S. Goverment Printing Office, 1992, 458.
Pektaş, Ö., Kalyoncu, A., Mirsal, H., Pektaş, A., Şatır, T, Beyazyürek, M.; Different forms (oral and implant) of naltrexone use in relapse prevention on heroin addicts: a controlled clinical trial up to 6 months follow up. American Academy of Addiction Psychiatry , 10 th Annual Meeting and Symposium, December 2-5, 1999, Nassau Marriott Resort, Nassau, Bahamas.
Kalyoncu, A., Şatır, T., Mirsal, H., Pektaş, Ö., Beyazyürek, M.; Naltrexone implant in opiate dependence: sociodemographic variables and evaluation of psychiatric symptoms in the first two months of he first naltrexone implantation. American Academy of Addiction Psychiatry , 10 th Annual Meeting and Symposium, December 2-5, 1999, Nassau Marriott Resort, Nassau, Bahamas.
Pektaş, Ö., Kalyoncu, A., Mirsal, H., Gooberman. L.L., Beyazyürek, M.; Different forms (oral and implant) of naltrexone use in relapse prevention on heroin addicts: a controlled clinical trial up to 6 months follow up (preliminary results). XXI Colllegium Internationale, Neuro-Psycopharmacologicum Congress, July 12-16, 1998, Glosgow, U.K.
Pektaş, Ö., Şatır, T; An overview on naltrexone implant treatment outcomes in Anatolia Clinics for Addiction Treatment. Rapid Opiate Detoxification Under Anesthesia Or Sedation and Post-Detox Management Using Naltrexone. A Two Day International Symposium, June 17-18th 1999, Berlin, Germany.
Hollister, L.; Report of the national research council commitee on clinical evaluation of narcotic antagonists: clinical evaluation of naltrexone treatment of dependent individual. Arch Gen Psychiatry 33:335-340, 1978.
Pfohl, D., Allen, J., Atkinson, R. et al.;Trexan (naltrexone hydrochloride): a review of hepatic toxicityat at high dosage, in Problems of Drug Dependence 1985, NIDA Res Monogr 67 (Publ No ADM-86-1448). Edited by Harris LS. Rockville, MD, U.S. Department of Health and Human Services, 1986, 66-72.
Arndt, I.O., Cacciola, J.S, McLellan, A.T. et al.; A re-evaluation of naltrexone toxicity in recovering opiate addicts, in Problems of Drug Dependence 1985, NIDA Res Monogr 67. Edited by Harris, L.S., Rockville, M.D., U.S.; Department of Health and Human Services, 1986, 525.
Christian, M.A.; Reproductive toxicity and teratology evaluation of naltrexone. J Clin Psychiatry 45:7-10,1984.
Maany, L, O'Brien, C.P., Woody, G.; Interaction between thioridazine and naltrexone (letter). Am J Psychiatiy 144:966, 1987.
Hubbel, C.L., Czirr, S.A., Reid, L.D.; Persistence and specifity of small doses of morphine on intake of alcoholic beverages. Alcohol 4:149-156, 1987.
Reid, L.D., Hunter, G.A.; Morphine and naloxone modulate intake of ethanol. Alcohol 1:33-37, 1984.
DeWitte.; Nalozone reduces alcohol intake in a free-choice procedure even when both drinking bottles contain saccharin sodium or quinine substances. Neuropsychobiology 12:73-77, 1984.
Samson, H.H., Doyle, T.E; Oral ethanol self-administration in the rat:effect of nalozone. Pharmacol Bi-ochem Behav 22:91-99, 1985.
Volpicelli, J.R., Davis, M.A., Olgin, J.E.; Naltrexone blocks the postshock increase of ethanol consumption. Life Sei 38:841-847, 1986.
Volpicelli, J.R., O'Brien, C.P.. Alterman, A.I. et al.; Naltrexone and the treatment of alcohol dependence: initial observations, in Opioids, Bulimia, and Alcohol Abuse and Alcoholism. Edited by Reid LB. New York, Springer-Verlag New York, 1990, 195-214.
Volpicelli, J.R., Alterman, A.I., Hayashida, M. et al.; Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49:876-880, 1992.
O’Malley, S.S., Jaffe, A., Chang, G. et al; Naltrexone in the treatment of alcohol dependence: preliminary findings, in Novel Pharmacological Interventions for Alcoholism. Edited by Naranjo CA, Sellers EM. New York, Springer-Verlag New York, 1991, 148-157
O’Malley, S.S., Jaffe, A., Chang, G. et al; Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 49:881-887, 1992.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Journal of Dependence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
...